Lisata Therapeutics, Inc. · NASDAQ:LSTA
Lisata Therapeutics — NeoStem — Investor Presentation (March 2009)
24 slides from Lisata Therapeutics's investor presentation, Mar 11, 2009
Slide 1: NeoStem Overview
Exhibit 99.1 NeoStem« Overview Robin Smith, MD, MBA CEO and Chairman of the Board (NYSE Alternext US: NBS) March 11, 2009
Slide 2: Forward Looking Statements
Forward Looking Statements Certain statements in this presentation constitute “onvarc-looking statements" within the meaning of the Pavate Secures Litigation Reform Act of 1995. ‘These statements incude statements relating to NeoStem, In. (the “Company) in general as weil as with respect to the Comp
Slide 3: NeoStem
NeoStem Listed on the NYSE Alternext US (ticker: NBS) Have completed approximately $16 Million in financing through Nov 2008 Leading operator of commercial autologous adult stem cell bank Pioneering pre-disease collection, processing and long-term storage of stem cells from adult donors for their ow
Slide 4: Adult Stem Cell Collection
Adult Stem Cell Collection = NeoStem has created a safe and minimally invasive way for adults to have their stem cells collected today and stored for future use NeoStem’s platform enables doctors and patients ready access to their cells as the therapies become available in the future Collecting Own
Slide 5: 70+ Diseases Treated w/Stem Cells
70+ Diseases Treated w/Stem Cells Results for many have been quite encouraging Heart Disease “It saved my life... my own stem cells.” BERNIE Adult Stem Cell Heart Recipient Lupus ly Lupus has been in remission for more than 5 years.” KatHy Adult Stem Cell Recipient Multiple Sclerosis “Stem Cells hel
Slide 6: Adult Stem Cells are in the news...
Adult Stem Cells are in the news... HM
Slide 7: Virtually All Therapeutic Areas
Virtually All Therapeutic Areas Over 2313 Adult Stem Cell Clinical Trials = By 2009, it is forecasted the first autologous products will be on the market in both orthopaedic and cardiovascular markets.* = By 2017, it is forecasted that a minimum of 16 stem cells products will be through the FDA and
Slide 8: Projected Stem Cell Therapy Sales
Projected Stem Cell Therapy Sales $9,000,000 $8,000,000 57,000,000 ® 6 $6,000,000 wn — $6,000,000 oO 384,000,000 = = 53,000,000 $2,000,000 $1,000,000 $30 Stem Cell Therapy: A $20 billion worldwide market by 2010 Source: Frost & Sullivan US Alone Source: Robert Young, RRY Publications, February $7,04
Slide 9: Our Current Revenue Model
Our Current Revenue Model = Current: o Collection center fees Collection from patients Processing patient cells Storage (recurring revenue) Usage Fees oo°0 0 = Potential: o Supplier of stem cells for research Collection fees for trials Government/military contracts SBIR grants Licensing of technolog
Slide 10: Exclusive World Wide VSEL License
Exclusive World Wide VSEL License Very Small Embryonic-Like (VSELs) Stem Cells = Each of us has a population of very primitive embryonic like stem cells that have remained dormant in our bodies since birth o Can be mobilized in the blood using NeoStem Process o Should be easily recovered o Cryoprese
Slide 11: Very-Small Embryonic-like Stem Cells (VSELs)
Very-Small Embryonic-like Stem Cells (VSELs) VSELs
Slide 12: Leukemia (2006), 1-7
Leukemia (2006), 1-7 Morphological and molecular characterization of novel population of CXCR4* SSEA-4 * Oct-4* very small embryonic-like cells purified from human cord blood — preliminary report M Kucia', M Halasa”, M Wysoczynski', M Baskiewicz-Masiuk?, $ Moldenhawer', € Zuba-Surma', R Czajka, W Wo
Slide 13: Intellectual Property
Intellectual Property Patent Applications Pending on Platform Business: Collection of adult stem cells from peripheral blood of healthy individuals for future use to treat various diseases of the individual” ° o Process by which NeoStem prepares and stores stem cells collected from peripheral blood
Slide 14: China Expansion
— China Expansion In November 2008 NeoStem Signed: = a Share Exchange Agreement pursuant to which NeoStem agreed to enter into a series of contractual arrangements with Shandong New Medicine Research Institute of Integrated Traditional and Western Medicine Limited Liability Company, a China limited
Slide 15: NeoStem's Future Plan
— NeoStem’s Future Plan = Established and highly profitable traditional pharma business in China underpins stem cell platform rollout = Innovative and vertically-integrated regenerative medicine product offering and delivery platform provides high growth opportunity = Technological, R&D and manageme
Slide 16: Proposed Combined Company
— Proposed Combined Company CBMs pars revenues and earnings provide certain stability that should be able to underpin the R&D, production and sales of pharmaceutical stem cell rollout Suzhou Erye products as well as chemicals used in pharmaceutical products. NBS brings innovative stem cell technolog
Slide 17: China Biopharmaceuticals Holdings, Inc.
— China Biopharmaceuticals Holdings, Inc. (Majority shareholding in — Suzhou Erye Pharmaceutical) Pharma revenues and earnings © Established and highly profitable traditional pharma business located in Suzhou, Jiangsu provide certain Stability that Province should be able to o R&D, production and sa
Slide 18: Stem Cell Businesses
— Stem Cell Businesses = Treatment © Provision of regenerative medicine therapies using neural stem cells for the treatment of a variety of CNS (central nervous system) conditions such as ALS, cerebral atrophy, cerebral palsy, external blunt force traumas, Parkinson's Disease, spinal cord injuries,
Slide 19: Stem Cell Businesses
— Stem Cell Businesses =» R&D © Research and commercial development on VSEL (Very Small Embryonic Like) stem cell technology with NBS and its US R&D partner, the University of Louisville, the institution at which the VSEL technology was developed and at which research with NBS is continuing © Establ
Slide 20: Shandong Red Cross Hospital Group (SRC)
— Shandong Red Cross Hospital Group* (SRC) SRC is well- connected and an appealing springboard for the roll out of VSEL technology applications and other stem cell activities into China Pioneer in the field of regenerative medicine in China © Since 2004, providing regenerative medicine therapies for
Slide 21: Transaction Rationale
— Transaction Rationale An opportunity to . Regulatory Benents ‘cerned vk © iress mismatch in regenerative medicine regulatory regimes create ad pool ane = Stem cell therapy, R&D and IP development led by the US, but pace of resources and commercialization hampered by FDA and related approval proces
Slide 22: Current Advisory Board Members
Current Advisory Board Members Wayne A, Marasco, M.D., Ph.O. Chairman - Chairman of Scientific Advisory Board. Associate Professor Department of Cancer and Immunology & AIDS at the Dana-Farber Cancer Insitute and Associate Professor of Medicine at Harvard Medical School, He is taking the lead in exp
Slide 23: Comparables
— Comparables Maret rie a an 6-209 | ‘Alleamount USD mations exe fore share dot hr pre denote el eure) Shore SB Wek ofS: cet UTM LTMLIMINt RG Total RRQ Book ie evjeart cap ‘cets MaCap company eter _| price “high "Wii _tcap vale Revenue EBITDA _Income_ Assets Value Ca/fav_EV/Rav OA _/EBTOA P/E /8 tau
Slide 24: Contact Information
Contact Information Robin Smith, MD MBA NeoStem, Inc. Chairman & CEO 420 Lexington Avenue Direct: (212) 584-4174 Suite 450 Email: rsmith@neostem.com New York, NY 10170 Main: (212) 584-4180 Fax: (646) 514-7787 www.neostem.com 1.888.STEM BANK